No abstract available
Keywords:
IMCgp100; MEK inhibitors selumetinib; checkpoint inhibitors; immunotherapy; tumor infiltrating lymphocytes; uveal melanoma.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Clinical Trials, Phase III as Topic
-
Costimulatory and Inhibitory T-Cell Receptors / antagonists & inhibitors
-
Humans
-
Immunotherapy / methods*
-
Immunotherapy / trends
-
Liver Neoplasms / mortality
-
Liver Neoplasms / secondary
-
Liver Neoplasms / therapy*
-
MAP Kinase Signaling System / drug effects
-
Melanoma / mortality
-
Melanoma / pathology
-
Melanoma / secondary
-
Melanoma / therapy*
-
Skin Neoplasms / mortality
-
Skin Neoplasms / pathology*
-
Treatment Outcome
-
Uveal Neoplasms / mortality
-
Uveal Neoplasms / pathology
-
Uveal Neoplasms / secondary
-
Uveal Neoplasms / therapy*
Substances
-
Costimulatory and Inhibitory T-Cell Receptors